Condition: Rectal Cancer · Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
The objective of this project is to determine in a non-invasive manner (fecal samples) the predictive value of the intestinal microbiota and the presence of genotoxin-producing bacteria on the response to neoadjuvant treatment in rectal cancer. This could lead to a better understanding and selection of patients for personalized treatment in rectal cancer.
This description comes directly from the study's public registry record.
Aurore MOUSSION, MD · 0467612446 · Aurore.Moussion@icm.unicancer.fr
Always discuss trial participation with your own doctor first.
| Institut régional du Cancer de Montpellier | Montpellier, Hérault, France | Recruiting |
| CHU Clermont-Ferrand | Clermont-Ferrand, Puy De Dôme, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04103567